Neuronetics, Inc. STIM
Set alert
As of Nov 2, 10:54 AM ET
- YTD
- +60.14%
- 1 year
- -16.60%
- Open
- 2.34
- Prev close
- 2.25
- Mkt cap
- 169.16M
- Vol
- 237.24K
- Avg vol
- 1.62M
- EPS
- -0.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.20
- High
- 2.37
- Forward P/E
- -2.15
- Beta
- 2.22
- Short ratio
- 4.05
- Inst. own
- 53.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 1.02
- 200-d avg
- 1.94
- 1y target
- 2.67
News
-
1 month ago benzinga.com
B. Riley Securities Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5
B. Riley Securities analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global…
-
2 months ago benzinga.com
Neuronetics Narrows FY2026 Sales Guidance from $160.000M-$166.000M to $160.000M-$164.000M vs $161.125M Est
Neuronetics (NASDAQ:STIM) narrows FY2026 sales outlook from $160.000 million-$166.000 million to $160.000 million-$164.000 million vs $161.125 million estimate.
-
2 months ago benzinga.com
Neuronetics Q2 EPS $(0.05) Beats $(0.13) Estimate, Sales $41.568M Beat $40.175M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.13) by 58.33 percent. This is a 66.67 percent increase over losses of $(0.15)…
-
3 months ago benzinga.com
Neuronetics Appoints Nir Naor CFO, Effective July 23,
Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional…
3 months ago benzinga.com
Why Is Neuronetics Stock Soaring Monday?
BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. Read the details here.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's regular session. The company's market cap stands at $33.0 million. Advanced Biomed (NASDAQ:ADVB) stock…
-
3 months ago benzinga.com
BTIG Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5
BTIG analyst Sam Eiber initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
-
5 months ago benzinga.com
Neuronetics Collaborates With ANT Neuro To Expand NeuroStar Advanced Therapy System
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…
-
6 months ago benzinga.com
Full Transcript: Neuronetics Q1 2026 Earnings Call
Full Transcript: Neuronetics Q1 2026 Earnings Call
-
6 months ago benzinga.com
Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$166.000M vs $162.467M Est
Business OutlookFor the second quarter of 2026, the Company expects total revenue growth in the mid-single digits.For the full year 2026, Neuronetics continues to expect:Total revenue between $160…
-
6 months ago benzinga.com
Neuronetics Q1 EPS $(0.16) Beats $(0.17) Estimate, Sales $34.454M Beat $34.183M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 23.81 percent increase over losses of $(0.21)…
6 months ago benzinga.com
Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan
This week's deal activity spans gaming, healthcare, energy, and private equity, with activist sales pushes and a slew of bankruptcies.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
6 months ago benzinga.com
Neuronetics Initiates Workforce Reduction Impacting Up To 5% Of Employees, Expects ~$200K Restructuring Charges And ~$2.5-$3M Annualized Savings
On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees. The reduction is part of a broader effort…
-
6 months ago benzinga.com
Neuronetics CFO Steven E. Pfanstiel To Depart, Effective May 1; Reiterates Q1, FY26 Outlook
Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from…
-
7 months ago benzinga.com
Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $3
Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $7 to $3.
-
7 months ago benzinga.com
Neuronetics Sees FY2026 Sales $160.000M-$166.000M vs $164.167M Est
Neuronetics (NASDAQ:STIM) sees FY2026 sales of $160.000 million-$166.000 million vs $164.167 million analyst estimate.
-
7 months ago benzinga.com
Neuronetics Q4 EPS $(0.10) Beats $(0.11) Estimate, Sales $41.777M Beat $40.667M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 6.54 percent. This is a 70.59 percent increase over losses of $(0.34)…
-
7 months ago benzinga.com
Earnings Scheduled For March 17, 2026
Earnings Scheduled For March 17, 2026
-
8 months ago benzinga.com
Peering Into Neuronetics Inc's Recent Short Interest
Peering Into Neuronetics Inc's Recent Short Interest
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
8 months ago benzinga.com
Why Teradata Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Why Teradata Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
8 months ago benzinga.com
Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On?
Neuronetics shares jumped 41% in after-hours trading following strong preliminary fourth-quarter 2025 revenue results.
-
8 months ago benzinga.com
Neuronetics Reports Q4 Preliminary Revenue $41.8M, FY25 Revenue $149.2M
Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the…
11 months ago benzinga.com
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November
-
12 months ago benzinga.com
Neuronetics Lowers FY2025 Sales Guidance from $149.000M-$155.000M to $147.000M-$150.000M vs $151.030M Est
Neuronetics (NASDAQ:STIM) lowers FY2025 sales outlook from $149.000 million-$155.000 million to $147.000 million-$150.000 million vs $151.030 million estimate.
-
12 months ago benzinga.com
Neuronetics Q3 EPS $(0.13) Misses $(0.10) Estimate, Sales $37.297M Miss $38.055M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 26.21 percent. This is a 70.45 percent increase over losses of…
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
New York Medicaid To Cover Neuronetics' TMS Therapy For Major Depressive Disorder Starting October 2025
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…
-
1 year ago benzinga.com
Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $7
Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $8 to $7.
-
1 year ago benzinga.com
Neuronetics Affirms FY2025 Sales Guidance of $149.000M-$155.000M vs $150.673M Est
Neuronetics (NASDAQ:STIM) affirms FY2025 sales outlook from $149.000 million-$155.000 million to $149.000 million-$155.000 million vs $150.673 million estimate.
-
1 year ago benzinga.com
Neuronetics Sees Q3 Sales $37.000M-$39.000M vs $38.395M Est
Neuronetics (NASDAQ:STIM) sees Q3 sales of $37.000 million-$39.000 million vs $38.395 million analyst estimate.
-
1 year ago benzinga.com
Neuronetics Q2 EPS $(0.15) Misses $(0.08) Estimate, Sales $38.108M Beat $36.612M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.08) by 94.81 percent. This is a 54.55 percent increase over losses of…
-
1 year ago benzinga.com
Neuronetics Publishes Real-World Data Showing Antidepressant Effects Of NeuroStar TMS In Adolescents And Young Adults
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth…
-
1 year ago benzinga.com
Neuronetics Appoints Steven Pfanstiel As CFO, Effective July 15, 2025; Reaffirms Q2, FY25 Guidance Citing Integration Of Greenbrook Operations And Continued Progress Across Key Growth Drivers
Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
Neuronetics Q1 EPS $(0.21) Misses $(0.14) Estimate, Sales $31.98M Beat $29.07M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.14) by 50 percent. This is a 22.22 percent increase over losses of $(0.27)…
-
1 year ago benzinga.com
Neuronetics Reports Updated Q4 Results; Net Loss $(0.33)
Fourth Quarter 2024 Results for the Three Months Ended December 31, 2024a $0.6 million reduction in the 2024 bonus accrual that the Company assumed in connection with its acquisition of Greenbrook,…
-
1 year ago benzinga.com
Canaccord Genuity Maintains Buy on Neuronetics, Raises Price Target to $8
Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $8.
-
1 year ago benzinga.com
Citizens Capital Markets Maintains Market Outperform on Neuronetics, Raises Price Target to $7
Citizens Capital Markets analyst Daniel Stauder maintains Neuronetics (NASDAQ:STIM) with a Market Outperform and raises the price target from $3 to $7.
-
1 year ago benzinga.com
Neuronetics Expects Q1 Revenue Of $28M-$30M Vs $21.02M Est, FY25 Revenue Of $145M-$155M Vs $93.55M Est
Business OutlookFor the first quarter of 2025, the Company expects total worldwide revenue between $28.0 million and $30.0 million.For the full year 2025, the Company expects total worldwide revenue…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session